Clotilde Fuentes-Orozco

Dr. Clotilde Fuentes-Orozco

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2004 in Clinical Nutrition
Verified
Journal Article
Closed access
CFClotilde Fuentes-Orozco
Clotilde Fuentes-Orozco
RARoberto Anaya-Prado
Roberto Anaya-Prado
AGAlejandro González-Ojeda
Alejandro González-Ojeda
HAHumberto Arenas-Márquez
Humberto Arenas-Márquez
CCCarlos Cabrera-Pivaral
Carlos Cabrera-Pivaral
LBLuis M Barrera-Zepeda
Luis M Barrera-Zepeda

21 July 2015 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
VAVíctor Fernando Andrade-Dávila
Víctor Fernando Andrade-Dávila
Mariana Chávez-TostadoMariana Chávez-Tostado
Mariana Chávez-Tostado
CDCarlos Dávalos-Cobián
Carlos Dávalos-Cobián
JGJesús García-Correa
Jesús García-Correa
AMAlejandro Montaño-Loza
Alejandro Montaño-Loza
AGAlejandro González-Ojeda
Alejandro González-Ojeda
Acute pancreatitis is the most common major complication after endoscopic retrograde cholangiopancreatography (ERCP). Many drugs have been evaluated for prophylaxis, including nonsteroidal anti-inflammatory drugs (NSAIDs), which are potent inhibitors of phospholipase A2 and play a role in the pathogenesis of acute pancreatitis. Rectal NSAIDs have been shown in prospective studies to decrease the incidence of this complication, but the indication is not generalized in clinical practice. The aim of this study was to evaluate the efficacy of rectal administration of indomethacin in reducing the incidence of post-ERCP pancreatitis in high-risk patients. This was a controlled clinical trial where patients with an elevated risk of developing post-ERCP pancreatitis were assigned to receive 100 mg of rectal indomethacin or a 2.6 g suppository of glycerin immediately after ERCP, without placement of a pancreatic stent. The patients were determined to be at high risk based on validated patient- and procedure-related risk factors. Post-ERCP pancreatitis was defined as the presence of new upper abdominal pain, hyperamylasemia/hyperlipasemia (at least three times the upper limit) 2 hours after the procedure and hospitalization at least 48 hours because of the complication. Pancreatitis severity was defined according to Cotton’s criteria. One hundred sixty-six patients were included; 82 in the study group and 84 in the placebo group. Patients had at least one major and/or two minor risk factors for developing post-ERCP pancreatitis. The incidence of the complication was 4.87 % (4/82) in the study group and 20.23 % (17/84) in the placebo group; this difference was significant (P = 0.01). According to Cotton’s criteria, 17 patients (80.9 %) developed mild pancreatitis and 4 (19.1 %) had moderate pancreatitis; 3 of these 4 patients belonged to the placebo group (P = 0.60). Based on these results, an absolute risk reduction of 0.15 (15 %), a relative risk reduction of 0.75 (75 %) and a number needed to treat of 6.5 patients were calculated to prevent an episode of post-ERCP pancreatitis. There was no mortality. Rectal indomethacin reduced the incidence of post-ERCP pancreatitis among patients at high risk of developing this complication. National Clinical Trials NCT02110810 . Date April 7, 2014.

30 June 2022 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
FCFrancisco José Barbosa Camacho
Francisco José Barbosa Camacho
OROlaya Moramay Romero-Limón
Olaya Moramay Romero-Limón
JIJuan Carlos Ibarrola-Peña
Juan Carlos Ibarrola-Peña
YAYolanda Lorelei Almanza-Mena
Yolanda Lorelei Almanza-Mena
KPKevin Josué Pintor-Belmontes
Kevin Josué Pintor-Belmontes
AGAlejandro González-Ojeda
Alejandro González-Ojeda
Depression and anxiety are common after months of social isolation, and they can have a negative impact on anyone's quality of life if they are not treated promptly and appropriately. The aim of this study was to determine if the change to online modality courses and the presence of depression or anxiety symptoms during the COVID-19 pandemic was associated with a difference in the college student’s academic achievement. This study was a cross-sectional survey in which we used the Patient Health Questionnaire-9 (PHQ-9) and the General Anxiety Disorder-7 (GAD-7). Also, we examined the students' perceptions of their academic performance using the Academic Self-Concept Scale (ASCS). A total of 610 students responded to the survey. The average score on the Academic Self-Concept Scale was 2.76 ± 0.35, the students presented a risk of 61.5% for possible depressive disorder and 52.1% for possible generalized anxiety disorder. The intensity of depression and anxiety symptoms had a significant effect on Academic Self-Concept Scale scores (p < 0.001 and p < 0.05, respectively). The findings indicate that the COVID-19 pandemic has had a direct effect on students' mental health and academic performance.

1 July 2008 in Journal of Parenteral and Enteral Nutrition
Verified
Journal Article
Closed access
PDF file
CFClotilde Fuentes-Orozco
Clotilde Fuentes-Orozco
GCGabino Cervantes‐Guevara
Gabino Cervantes‐Guevara
IMIvette Muciño‐Hernández
Ivette Muciño‐Hernández
ALAlejandro López‐Ortega
Alejandro López‐Ortega
GAGabriela Ambriz‐González
Gabriela Ambriz‐González
AGAlejandro González-Ojeda
Alejandro González-Ojeda

23 December 2010 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JGJorge Gómez-Hernández
Jorge Gómez-Hernández
AOAlba Lorena Orozco-Alatorre
Alba Lorena Orozco-Alatorre
MDMarisela Domínguez-Contreras
Marisela Domínguez-Contreras
AOAntonio Oceguera-Villanueva
Antonio Oceguera-Villanueva
SGSalvador Gómez-Romo
Salvador Gómez-Romo
AGAlejandro González-Ojeda
Alejandro González-Ojeda
Background: Dexamethasone has been reported to reduce postoperative symptoms after different surgical procedures. We evaluated the efficacy of preoperative dexamethasone in ameliorating postoperative nausea and vomiting (PONV), and pain after mastectomy. Methods: In this prospective, double-blind, placebo-controlled study, 70 patients scheduled for mastectomy with axillary lymph node dissection were analyzed after randomization to treatment with 8 mg intravenous dexamethasone (n = 35) or placebo (n = 35). All patients underwent standardized procedures for general anesthesia and surgery. Episodes of PONV and pain score were recorded on a visual analogue scale. Analgesic and antiemetic requirements were also recorded. Results: Demographic and medical variables were similar between groups. The incidence of PONV was lower in the dexamethasone group at the early postoperative evaluation (28.6% vs. 60%; p = 0.02) and at 6 h (17.2% vs. 45.8%; p = 0.03). More patients in the placebo group required additional antiemetic medication (21 vs. 8; p = 0.01). Dexamethasone treatment significantly reduced postoperative pain just after surgery (VAS score, 4.54 ± 1.55 vs. 5.83 ± 2.00; p = 0.004), at 6 h (3.03 ± 1.20 vs. 4.17 ± 1.24; p < 0.0005) and at 12 h (2.09 ± 0.85 vs. 2.54 ± 0.98; p = 0.04). Analgesics were required in more patients of the control group (21 vs. 10; p = 0.008). There were no adverse events, morbidity or mortality. Conclusions: Preoperative intravenous dexamethasone (8 mg) can significantly reduce the incidence of PONV and pain in patients undergoing mastectomy with axillary dissection for breast cancer. Trial registration number: NCT01116713

1 January 2014 in World Journal of Gastroenterology
Verified
Journal Article
Open access
AGAlejandro González-Ojeda
Alejandro González-Ojeda
GCGabino Cervantes-Guevara
Gabino Cervantes-Guevara
MCManuela Chávez-Sánchez
Manuela Chávez-Sánchez
CDCarlos Dávalos-Cobián
Carlos Dávalos-Cobián
SOSusana Ornelas-Cázares
Susana Ornelas-Cázares
CFClotilde Fuentes-Orozco
Clotilde Fuentes-Orozco
To validate whether the platelet count/spleen size ratio can be used to predict the presence of esophageal varices in Mexican patients with hepatic cirrhosis. This was an analytical cross-sectional study to validate the diagnostic test for hepatic cirrhosis and was performed between February 2010 and December 2011. Patients with a diagnosis of hepatic cirrhosis were included and stratified using their Child-Pugh score. Biochemical parameters were evaluated, and ultrasound was used to measure the longest diameter of the spleen. The platelet count/spleen diameter ratio was calculated and analyzed to determine whether it can predict the presence of esophageal varices. Upper gastrointestinal endoscopy was used as the gold standard. Sensitivity and specificity, positive and negative predictive values, and positive and negative likelihood ratios were determined, with the cutoff points determined by receiver-operating characteristic curves. A total of 91 patients were included. The mean age was 53.75 ± 12 years; 50 (54.9%) were men, and 41 (45.0%) women. The etiology of cirrhosis included alcohol in 48 (52.7%), virally induced in 24 (26.3%), alcoholism plus hepatitis C virus in three (3.2%), cryptogenic in nine (9.8%), and primary biliary cirrhosis in seven (7.6%). Esophageal varices were present in 73 (80.2%) patients. Child-Pugh classification, 17 (18.6%) patients were classified as class A, 37 (40.6%) as class B, and 37 (40.6%) as class C. The platelet count/spleen diameter ratio to detect esophageal varices independent of the grade showed using a cutoff value of ≤ 884.3, had 84% sensitivity, 70% specificity, and positive and negative predictive values of 94% and 40%, respectively. Our results suggest that the platelet count/spleen diameter ratio may be a useful tool for detecting esophageal varices in patients with hepatic cirrhosis.